Themis Medicare Intrinsic Value
Themis Medicare intrinsic value. Themis Medicare (THEMISMED) median intrinsic value is ₹225.78 from 10 valuation models (range ₹34–₹282), vs current price ₹112.89 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Read THEMISMED ex-dividend dates for the complete payout history and dividend yield track record.
THEMISMED Valuation Methods Summary — DCF, Graham Number & P/E
Themis Medicare intrinsic value across 10 models vs current price ₹112.89 — upside/downside and value range per method. For current market price and key ratios, visit Themis Medicare share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹84.48 | ₹67.58 - ₹101.38 | -25.2% | EPS: ₹3.84, Sector P/E: 22x |
| Book Value Method | asset | ₹282.23 | ₹254.01 - ₹310.45 | +150.0% | Book Value/Share: ₹443.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹225.78 | ₹203.20 - ₹248.36 | +100.0% | Revenue/Share: ₹386.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹225.78 | ₹203.20 - ₹248.36 | +100.0% | EBITDA: ₹56.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹282.23 | ₹225.78 - ₹338.68 | +150.0% | CF Growth: 1.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹33.87 | ₹30.48 - ₹37.26 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹59.33 | ₹53.40 - ₹65.26 | -47.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹225.78 | ₹203.20 - ₹248.36 | +100.0% | ROE: 9.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹195.71 | ₹176.14 - ₹215.28 | +73.4% | EPS: ₹3.84, BVPS: ₹443.33 |
| Dividend Yield Method | dividend | ₹33.87 | ₹30.48 - ₹37.26 | -70.0% | DPS: ₹0.50, Target Yield: 2.5% |
THEMISMED Intrinsic Value vs Market Price — All Valuation Models
Themis Medicare fair value range ₹34–₹282 vs current market price ₹112.89 across 10 valuation models. Compare with THEMISMED DCF valuation to assess whether the stock is under or overvalued.
THEMISMED Intrinsic Value Analysis — Undervalued or Overvalued?
Themis Medicare median intrinsic value ₹225.78, current price ₹112.89 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of THEMISMED?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Themis Medicare (THEMISMED) is ₹225.78 (median value). With the current market price of ₹112.89, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹33.87 to ₹282.23, indicating ₹33.87 - ₹282.23.
Is THEMISMED undervalued or overvalued?
Based on our multi-method analysis, Themis Medicare (THEMISMED) appears to be trading below calculated value by approximately 100.0%.
THEMISMED Financial Health — Key Ratios vs Industry Benchmarks
Themis Medicare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.24 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 9.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.58x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
THEMISMED Cash Flow Quality — Operating & Free Cash Flow
Themis Medicare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-3 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹35 Cr | ₹29 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹22 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹34 Cr | ₹26 Cr | Positive Free Cash Flow | 8/10 |